Loading…
Lobbying Spend
$74.2M
Filings
150
Firms Hired
4
Active Period
2004–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Farm, Food, and National Security Act of 2026
2026 · third_quarter · Firm: MONUMENT ADVOCACY
Issues related to general agriculture, animal health, foreign animal disease, regulatory processes, USDA Programs, the farm bill incl HR 7567 + S5526, wildlife services, oral rabies vaccination program, and national vaccine banks.
Client expense: — · Firm income: $50,000
Matched citations: HR 7567
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
2026 · third_quarter · Firm: MONUMENT ADVOCACY
Issues related to FY27 agricultural appropriations including HR8646
Client expense: — · Firm income: $50,000
Matched citations: HR8646
Issues related to general agriculture, animal health, foreign animal disease, regulatory processes, USDA Programs, the farm bill incl HR 7567 + S5526, wildlife services, oral rabies vaccination program, and national vaccine banks.
Client expense: — · Firm income: $50,000
Matched citations: S5526
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
2026 · third_quarter · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client expense: $1,020,000 · Firm income: —
Matched citations: H.R. 1492
PAW Act of 2025
2026 · third_quarter · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Animal Health Issues related to One Health Issues Related to PAW Act (H.R. 1842) Farm, Food and National Security Act of 2026 (H.R. 7567) Issues related to the regulatory process Issues related to transboundary animal disease control and prevention Issues related to avian influenza Issues related to New World Screwworm Issues Related to Tax and Trade
Client expense: $1,020,000 · Firm income: —
Matched citations: H.R. 1842
Farm, Food, and National Security Act of 2026
2026 · third_quarter · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Animal Health Issues related to One Health Issues Related to PAW Act (H.R. 1842) Farm, Food and National Security Act of 2026 (H.R. 7567) Issues related to the regulatory process Issues related to transboundary animal disease control and prevention Issues related to avian influenza Issues related to New World Screwworm Issues Related to Tax and Trade
Client expense: $1,020,000 · Firm income: —
Matched citations: H.R. 7567
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
2026 · third_quarter · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client expense: $1,020,000 · Firm income: —
Matched citations: H.R. 842
ORPHAN Cures Act
2026 · third_quarter · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client expense: $1,020,000 · Firm income: —
Matched citations: H.R. 946
ORPHAN Cures Act
2026 · third_quarter · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client expense: $1,020,000 · Firm income: —
Matched citations: S. 1862
A bill to amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening tests.
2026 · third_quarter · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client expense: $1,020,000 · Firm income: —
Matched citations: S. 339
EPIC Act of 2025
2026 · third_quarter · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client expense: $1,020,000 · Firm income: —
Matched citations: S.832
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
2026 · second_quarter · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client expense: $710,000 · Firm income: —
Matched citations: H.R. 1492
PAW Act of 2025
2026 · second_quarter · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Animal Health Issues related to One Health Issues Related to PAW Act (H.R. 1842) Farm, Food and National Security Act of 2026 (H.R. 7567) Issues related to the regulatory process Issues related to transboundary animal disease control and prevention Issues related to avian influenza Issues related to New World Screwworm Issues Related to Tax and Trade
Client expense: $710,000 · Firm income: —
Matched citations: H.R. 1842
Farm, Food, and National Security Act of 2026
2026 · second_quarter · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Animal Health Issues related to One Health Issues Related to PAW Act (H.R. 1842) Farm, Food and National Security Act of 2026 (H.R. 7567) Issues related to the regulatory process Issues related to transboundary animal disease control and prevention Issues related to avian influenza Issues related to New World Screwworm Issues Related to Tax and Trade
Client expense: $710,000 · Firm income: —
Matched citations: H.R. 7567
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
2026 · second_quarter · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client expense: $710,000 · Firm income: —
Matched citations: H.R. 842
ORPHAN Cures Act
2026 · second_quarter · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client expense: $710,000 · Firm income: —
Matched citations: H.R. 946
ORPHAN Cures Act
2026 · second_quarter · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client expense: $710,000 · Firm income: —
Matched citations: S. 1862
A bill to amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening tests.
2026 · second_quarter · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client expense: $710,000 · Firm income: —
Matched citations: S. 339
EPIC Act of 2025
2026 · second_quarter · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client expense: $710,000 · Firm income: —
Matched citations: S.832
Farm, Food, and National Security Act of 2026
2026 · second_quarter · Firm: MONUMENT ADVOCACY
Issues related to general agriculture, animal health, regulatory processes, USDA Programs, the farm bill incl HR 7567, wildlife services, oral rabies vaccination program, and national vaccine banks.
Client expense: — · Firm income: $50,000
Matched citations: HR 7567
Student Loan Tax Elimination Act
2026 · first_quarter · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Animal Health Issues related to One Health Issues Related to PAW Act (H.R. 1842) Far, Food and National Security Act of 2024 (H.R. 8467) Issues related to the regulatory process Issues related to transboundary animal disease control and prevention Issues related to avian influenza Issues related to New World Screwworm Issues Related to Tax and Trade
Client expense: $1,165,000 · Firm income: —
Matched citations: H.R. 1842
Farm, Food, and National Security Act of 2024
2026 · first_quarter · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Animal Health Issues related to One Health Issues Related to PAW Act (H.R. 1842) Far, Food and National Security Act of 2024 (H.R. 8467) Issues related to the regulatory process Issues related to transboundary animal disease control and prevention Issues related to avian influenza Issues related to New World Screwworm Issues Related to Tax and Trade
Client expense: $1,165,000 · Firm income: —
Matched citations: H.R. 8467
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
2026 · first_quarter · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client expense: $1,165,000 · Firm income: —
Matched citations: H.R. 1492
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
2026 · first_quarter · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client expense: $1,165,000 · Firm income: —
Matched citations: H.R. 842
ORPHAN Cures Act
2026 · first_quarter · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client expense: $1,165,000 · Firm income: —
Matched citations: H.R. 946
Source: Senate LDA